CurveBeam AIASX:CVB -10.00% Net Current Asset Value is A$-0.01 as of Dec. 2025. The stock has 5 warning signs investors should review. Among 568 Medical Devices & Instruments companies, CurveBeam AI ranks worse than 176056.16% on this metric.
In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).
CurveBeam AI's net current asset value per share for the quarter that ended in Dec. 2025 was A$-0.01.
The historical rank and industry rank for CurveBeam AI's Net Current Asset Value or its related term are showing as below:
During the past 5 years, the highest Price-to-Net-Current-Asset-Value Ratio of CurveBeam AI was 20.06. The lowest was 20.06. And the median was 20.06.
ASX:CVB's Price-to-Net-Current-Asset-Value is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 5.1 * Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CurveBeam AI (ASX:CVB) Net Current Asset Value Explanation
Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."
The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]
Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.
One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.
Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.
CurveBeam AI Net Current Asset Value Related Terms
CurveBeam AI Net Current Asset Value Historical Data
* Premium members only.
The historical data trend for CurveBeam AI's Net Current Asset Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:CVB vs ABT, SYK, MDT: Net Current Asset Value Comparison
For the Medical Devices subindustry, CurveBeam AI's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CurveBeam AI Price-to-Net-Current-Asset-Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CurveBeam AI's Price-to-Net-Current-Asset-Value distribution charts can be found below:
* The bar in red indicates where CurveBeam AI's Price-to-Net-Current-Asset-Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Current Asset Value of A$-0.01 mean?
CurveBeam AI (ASX:CVB) has a Net Current Asset Value of A$-0.01 as of Dec. 2025. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on CurveBeam AI and its competitors. Over the past decade, CurveBeam AI's Net Current Asset Value has ranged from 20.06 to 20.06. According to the industry distribution chart, CurveBeam AI ranks #999999 out of 568 companies in the Medical Devices & Instruments industry.
Is CurveBeam AI's Net Current Asset Value too high?
CurveBeam AI's current Net Current Asset Value is A$-0.01. Over the past 10 years, this metric has ranged from a low of 20.06 to a high of 20.06. Based on the distribution chart, CurveBeam AI ranks #999999 out of 568 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers.
How does CurveBeam AI's Net Current Asset Value compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CurveBeam AI ranks #999999 out of 568 companies for Net Current Asset Value. This places CurveBeam AI in the lower half of its industry. The industry median Net Current Asset Value is 5.10. Historically, CurveBeam AI's own Net Current Asset Value has ranged from 20.06 to 20.06 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Current Asset Value for a Medical Devices & Instruments company?
The median Net Current Asset Value among Medical Devices & Instruments companies is 5.10, based on 568 companies in the industry. Companies in the top quartile (top 25%) have a Net Current Asset Value significantly above this median, while those in the bottom quartile fall well below. However, Net Current Asset Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Current Asset Value mean?
A high Net Current Asset Value can signal that a stock is expensive relative to its fundamentals. Ben Graham's net current asset value equals the per-share value of total current assets less total liabilities. View historical data on CurveBeam AI and its competitors. For the Medical Devices & Instruments industry, the median Net Current Asset Value is 5.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CurveBeam AI's current Net Current Asset Value is A$-0.01. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Net Current Asset Value of A$-0.01. The current Net Current Asset Value is A$-0.01. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Current Asset Value calculated?
Net Current Asset Value is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Net Current Asset Value is A$-0.01 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:CVB has been successfully added to your 